{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:11:54Z","timestamp":1790907114402,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hypercholesterolemia has posed a serious threat of heart diseases and stroke worldwide. Xanthine oxidase (XO), the rate-limiting enzyme in uric acid biosynthesis, is regarded as the root of reactive oxygen species (ROS) that generate atherosclerosis and cholesterol crystals. \u03b2-Hydroxy \u03b2-methylglutaryl-coenzyme A reductase (HMGR) is a rate-limiting enzyme in cholesterol biosynthesis. Although some commercially available enzyme inhibiting drugs have effectively reduced cholesterol levels, most of them have failed to meet potential drug candidates\u2019 requirements. Here, we have carried out an <jats:italic>in-silico<\/jats:italic> analysis of secondary metabolites that have already shown good inhibitory activity against XO and HMGR in a wet lab setup.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Out of 118 secondary metabolites reviewed, sixteen molecules inhibiting XO and HMGR were selected based on the IC<jats:sub>50<\/jats:sub> values reported in in vitro assays. Further, receptor-based virtual screening was carried out against secondary metabolites using <jats:italic>GOLD Protein-Ligand Docking Software<\/jats:italic>, combined with subsequent post-docking, to study the binding affinities of ligands to the enzymes<jats:italic>. In-silico<\/jats:italic> ADMET analysis was carried out to explore their pharmacokinetic properties, followed by toxicity prediction through ProTox-II.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The molecular docking of amentoflavone (GOLD score 70.54, \u2206G <jats:sub>calc.<\/jats:sub> = \u2212\u200910.4 Kcal\/mol) and ganomycin I (GOLD score 59.61, \u2206G <jats:sub>calc.<\/jats:sub> = \u2212\u20096.8 Kcal\/mol) displayed that the drug has effectively bound at the competitive site of XO and HMGR, respectively. Besides, 6-paradol and selgin could be potential drug candidates inhibiting XO. Likewise, n-octadecanyl-O-\u03b1-D-glucopyranosyl (6\u2032\u2009\u2192\u20091\u2033)-O-\u03b1-D-glucopyranoside could be potential drug candidates to maintain serum cholesterol. <jats:italic>In-silico<\/jats:italic> ADMET analysis has shown that these sixteen metabolites were optimal within the categorical range compared to commercially available XO and HMGR inhibitors, respectively. Toxicity analysis through ProTox-II revealed that 6-gingerol, ganoleucoin K, and ganoleucoin Z are toxic for human use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This computational analysis supports earlier experimental evidence towards the inhibition of XO and HMGR by natural products. Further study is necessary to explore the clinical efficacy of these secondary molecules, which might be alternatives for the treatment of hypercholesterolemia.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-020-03162-5","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T12:02:43Z","timestamp":1609502563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Rishab","family":"Marahatha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saroj","family":"Basnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibek Raj","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakriti","family":"Budhathoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Aryal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bikash","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Lamichhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darbin Kumar","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-6489","authenticated-orcid":false,"given":"Niranjan","family":"Parajuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"issue":"6","key":"3162_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","volume":"121","author":"P Joseph","year":"2017","unstructured":"Joseph P, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121(6):677\u201394. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.308903..","journal-title":"Circ Res"},{"key":"3162_CR2","unstructured":"\u201cWHO,\u201d WHO, Raised Cholesterol. https:\/\/www.who.int\/gho\/ncd\/risk_factors\/cholesterol_text\/en\/ (accessed 5 Jul 2020)."},{"issue":"11","key":"3162_CR3","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1517\/17425255.4.11.1403","volume":"4","author":"IA Pikuleva","year":"2008","unstructured":"Pikuleva IA. Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering. Expert Opin Drug Metab Toxicol. 2008;4(11):1403\u201314. https:\/\/doi.org\/10.1517\/17425255.4.11.1403.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"3162_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1146\/annurev.cellbio.16.1.459","volume":"16","author":"JJ Repa","year":"2000","unstructured":"Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16(1):459\u201381. https:\/\/doi.org\/10.1146\/annurev.cellbio.16.1.459.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"8","key":"3162_CR5","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1194\/jlr.R004739","volume":"51","author":"D Weissglas-Volkov","year":"2010","unstructured":"Weissglas-Volkov D, Pajukanta P. Genetic causes of high and low serum HDL-cholesterol. J Lipid Res. 2010;51(8):2032\u201357. https:\/\/doi.org\/10.1194\/jlr.R004739.","journal-title":"J Lipid Res"},{"issue":"9","key":"3162_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/CIRCRESAHA.115.306807","volume":"117","author":"J Fu","year":"2015","unstructured":"Fu J, et al. The gut microbiome contributes to a substantial proportion of the variation in blood lipids. Circ Res. 2015;117(9):817\u201324. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306807.","journal-title":"Circ Res"},{"issue":"1","key":"3162_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.mcn.2009.07.013","volume":"43","author":"J-P Liu","year":"2010","unstructured":"Liu J-P, Tang Y, Zhou S, Toh BH, McLean C, Li H. Cholesterol involvement in the pathogenesis of neurodegenerative diseases. Mol Cell Neurosci. 2010;43(1):33\u201342. https:\/\/doi.org\/10.1016\/j.mcn.2009.07.013.","journal-title":"Mol Cell Neurosci"},{"key":"3162_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.plipres.2018.12.002","volume":"73","author":"X-H Yu","year":"2019","unstructured":"Yu X-H, Zhang D-W, Zheng X-L, Tang C-K. Cholesterol transport system: an integrated cholesterol transport model involved in atherosclerosis. Prog Lipid Res. 2019;73:65\u201391. https:\/\/doi.org\/10.1016\/j.plipres.2018.12.002..","journal-title":"Prog Lipid Res"},{"issue":"18","key":"3162_CR9","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1080\/14786419.2015.1108977","volume":"30","author":"SS Alvi","year":"2016","unstructured":"Alvi SS, Iqbal D, Ahmad S, Khan MS. Molecular rationale delineating the role of lycopene as a potent HMG-CoA reductase inhibitor: in vitro and in silico study. Nat Prod Res. 2016;30(18):2111\u20134. https:\/\/doi.org\/10.1080\/14786419.2015.1108977.","journal-title":"Nat Prod Res"},{"issue":"4","key":"3162_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0002-8703(00)90033-4","volume":"139","author":"RS Blumenthal","year":"2000","unstructured":"Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J. 2000;139(4):577\u201383. https:\/\/doi.org\/10.1016\/S0002-8703(00)90033-4.","journal-title":"Am Heart J"},{"key":"3162_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/164_2020_361","volume-title":"LDL-cholesterol-lowering therapy","author":"A Pirillo","year":"2020","unstructured":"Pirillo A, Norata GD, Catapano AL. LDL-cholesterol-lowering therapy. Berlin, Heidelberg: Springer Berlin Heidelberg; 2020."},{"issue":"4","key":"3162_CR12","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14779072.6.4.447","volume":"6","author":"HE Bays","year":"2008","unstructured":"Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Expert Rev Cardiovasc Ther. 2008;6(4):447\u201370. https:\/\/doi.org\/10.1586\/14779072.6.4.447.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"3162_CR13","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ijcard.2016.10.011","volume":"227","author":"M Mazidi","year":"2017","unstructured":"Mazidi M, Rezaie P, Karimi E, Kengne AP. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2017;227:850\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.011.","journal-title":"Int J Cardiol"},{"issue":"24","key":"3162_CR14","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","volume":"65","author":"RP Giugliano","year":"2015","unstructured":"Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol. 2015;65(24):2638\u201351. https:\/\/doi.org\/10.1016\/j.jacc.2015.05.001.","journal-title":"J Am Coll Cardiol"},{"key":"3162_CR15","doi-asserted-by":"publisher","unstructured":"Laufs U, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7). https:\/\/doi.org\/10.1161\/JAHA.118.011662.","DOI":"10.1161\/JAHA.118.011662"},{"issue":"9","key":"3162_CR16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJP. Lomitapide and Mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.001292.","journal-title":"Circulation"},{"key":"3162_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/B978-0-444-63438-2.00018-3","volume-title":"\u201cAtherosclerosis,\u201d in Biochemistry of Lipids, Lipoproteins and Membranes, Elsevier","author":"MW Huff","year":"2016","unstructured":"Huff MW, Daugherty A, Lu H. \u201cAtherosclerosis,\u201d in Biochemistry of Lipids, Lipoproteins and Membranes, Elsevier; 2016. p. 519\u201348."},{"key":"3162_CR18","volume-title":"StatPearls","author":"N Aziz","year":"2020","unstructured":"Aziz N, Jamil RT. Biochemistry, Xanthine Oxidase. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020."},{"key":"3162_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/B978-0-12-405885-9.00019-X","volume-title":"Diabetes: Oxidative Stress and Dietary Antioxidants, Elsevier","author":"JR Murrow","year":"2014","unstructured":"Murrow JR. Statins, Diabetic Oxidative Stress and Vascular Tissue. In: Diabetes: Oxidative Stress and Dietary Antioxidants, Elsevier; 2014. p. 183\u201390."},{"issue":"3","key":"3162_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/pr.58.3.2","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, B\u00e1tkai S, Kunos G. The Endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389\u2013462. https:\/\/doi.org\/10.1124\/pr.58.3.2.","journal-title":"Pharmacol Rev"},{"issue":"9","key":"3162_CR21","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.bbadis.2014.05.022","volume":"1842","author":"MG Battelli","year":"2014","unstructured":"Battelli MG, Bolognesi A, Polito L. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2014;1842(9):1502\u201317. https:\/\/doi.org\/10.1016\/j.bbadis.2014.05.022.","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"key":"3162_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","volume":"213","author":"J Maiuolo","year":"2016","unstructured":"Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. Int J Cardiol. 2016;213:8\u201314. https:\/\/doi.org\/10.1016\/j.ijcard.2015.08.109.","journal-title":"Int J Cardiol"},{"issue":"21","key":"3162_CR23","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1136\/heartjnl-2012-302249","volume":"98","author":"A Struthers","year":"2012","unstructured":"Struthers A, Shearer F. Allopurinol: novel indications in cardiovascular disease. Heart. 2012;98(21):1543\u20135. https:\/\/doi.org\/10.1136\/heartjnl-2012-302249.","journal-title":"Heart"},{"issue":"3","key":"3162_CR24","doi-asserted-by":"publisher","first-page":"201","DOI":"10.5830\/CVJA-2016-068","volume":"28","author":"M Zdrenghea","year":"2017","unstructured":"Zdrenghea M, Sitar-T\u01ceut A, Cismaru G, Zdrenghea D, Pop D. Xanthine oxidase inhibitors in ischaemic heart disease. Cardiovasc J Afr. 2017;28(3):201\u20134. https:\/\/doi.org\/10.5830\/CVJA-2016-068.","journal-title":"Cardiovasc J Afr"},{"issue":"3","key":"3162_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.nutres.2008.01.006","volume":"28","author":"E Devrim","year":"2008","unstructured":"Devrim E, Erg\u00fcder \u0130B, \u00d6zbek H, Durak \u0130. High-cholesterol diet increases xanthine oxidase and decreases nitric oxide synthase activities in erythrocytes from rats. Nutr Res. 2008;28(3):212\u20135. https:\/\/doi.org\/10.1016\/j.nutres.2008.01.006.","journal-title":"Nutr Res"},{"issue":"1","key":"3162_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/1871523011312010011","volume":"12","author":"J Saban-Ruiz","year":"2013","unstructured":"Saban-Ruiz J, Alonso-Pacho A, Fabregate-Fuente M, de la Puerta Gonzalez-Quevedo C. Xanthine oxidase inhibitor Febuxostat as a novel agent postulated to act against vascular inflammation. Anti-Inflamm Anti-Allergy Agents Med Chem. 2013;12(1):94\u20139. https:\/\/doi.org\/10.2174\/1871523011312010011.","journal-title":"Anti-Inflamm Anti-Allergy Agents Med Chem"},{"issue":"3","key":"3162_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ni.2001","volume":"12","author":"GK Hansson","year":"2011","unstructured":"Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204\u201312. https:\/\/doi.org\/10.1038\/ni.2001.","journal-title":"Nat Immunol"},{"issue":"4","key":"3162_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5830\/CVJA-2011-068","volume":"23","author":"M Mudau","year":"2012","unstructured":"Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction : the early predictor of atherosclerosis. Cardiovasc. J. Afr. 2012;23(4):222\u201331. https:\/\/doi.org\/10.5830\/CVJA-2011-068.","journal-title":"Cardiovasc. J. Afr."},{"issue":"5519","key":"3162_CR29","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","volume":"292","author":"ES Istvan","year":"2001","unstructured":"Istvan ES. Structural mechanism for statin inhibition of HMG-CoA Reductase. Science. May 2001;292(5519):1160\u20134. https:\/\/doi.org\/10.1126\/science.1059344.","journal-title":"Science"},{"issue":"2","key":"3162_CR30","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.abb.2010.09.028","volume":"505","author":"HM Miziorko","year":"2011","unstructured":"Miziorko HM. Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Arch Biochem Biophys. 2011;505(2):131\u201343. https:\/\/doi.org\/10.1016\/j.abb.2010.09.028.","journal-title":"Arch Biochem Biophys"},{"key":"3162_CR31","volume-title":"Endotext","author":"KR Feingold","year":"2020","unstructured":"Feingold KR. Cholesterol Lowering Drugs. In: Endotext. South Dartmouth (MA): MDText.com, Inc; 2020."},{"issue":"8","key":"3162_CR32","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","volume":"33","author":"AG Atanasov","year":"2015","unstructured":"Atanasov AG, et al. Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv. 2015;33(8):1582\u2013614. https:\/\/doi.org\/10.1016\/j.biotechadv.2015.08.001.","journal-title":"Biotechnol Adv"},{"issue":"3","key":"3162_CR33","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/molecules25030662","volume":"25","author":"T Linder","year":"2020","unstructured":"Linder T, et al. Design and Synthesis of a Compound Library Exploiting 5-Methoxyleoligin as Potential Cholesterol Efflux Promoter. Molecules. 2020;25(3):662. https:\/\/doi.org\/10.3390\/molecules25030662.","journal-title":"Molecules"},{"issue":"1","key":"3162_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/pro.3331","volume":"27","author":"SK Burley","year":"2018","unstructured":"Burley SK, et al. RCSB protein data Bank: sustaining a living digital data resource that enables breakthroughs in scientific research and biomedical education: RCSB protein data Bank. Protein Sci. 2018;27(1):316\u201330. https:\/\/doi.org\/10.1002\/pro.3331.","journal-title":"Protein Sci"},{"issue":"3TT","key":"3162_CR35","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1074\/jbc.M208307200","volume":"278","author":"K Okamoto","year":"2003","unstructured":"Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine Oxidoreductase: CRYSTAL STRUCTURE OF THE ENZYME-INHIBITOR COMPLEX AND MECHANISM OF INHIBITION. J Biol Chem. 2003;278(3TT):1848\u201355. https:\/\/doi.org\/10.1074\/jbc.M208307200.","journal-title":"J Biol Chem"},{"issue":"1","key":"3162_CR36","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1038\/s41467-018-07590-3","volume":"9","author":"S-Y Jiang","year":"2018","unstructured":"Jiang S-Y, et al. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nat Commun. 2018;9(1):5138. https:\/\/doi.org\/10.1038\/s41467-018-07590-3.","journal-title":"Nat Commun"},{"key":"3162_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ejmech.2017.11.071","volume":"143","author":"MD Santi","year":"2018","unstructured":"Santi MD, et al. Xanthine oxidase inhibitory activity of natural and hemisynthetic flavonoids from Gardenia oudiepe (Rubiaceae) in vitro and molecular docking studies. Eur J Med Chem. Jan. 2018;143:577\u201382. https:\/\/doi.org\/10.1016\/j.ejmech.2017.11.071.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"3162_CR38","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1021\/jf903515f","volume":"58","author":"E-K Kwon","year":"2010","unstructured":"Kwon E-K, et al. Flavonoids from the buds of Rosa damascena inhibit the activity of 3-Hydroxy-3-methylglutaryl-coenzyme a Reductase and angiotensin I-converting enzyme. J Agric Food Chem. 2010;58(2):882\u20136. https:\/\/doi.org\/10.1021\/jf903515f.","journal-title":"J Agric Food Chem"},{"issue":"18","key":"3162_CR39","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.2174\/156802612804910278","volume":"12","author":"R Guha","year":"2012","unstructured":"Guha R, Willighagen E. A survey of quantitative descriptions of molecular structure. Curr Top Med Chem. 2012;12(18):1946\u201356. https:\/\/doi.org\/10.2174\/156802612804910278.","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"3162_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0263-7855(93)85003-9","volume":"11","author":"CA Del Carpio","year":"1993","unstructured":"Del Carpio CA, Takahashi Y, Sasaki S. A new approach to the automatic identification of candidates for ligand receptor sites in proteins: (I) search for pocket regions. J Mol Graph. 1993;11(1):23\u20139. https:\/\/doi.org\/10.1016\/0263-7855(93)85003-9.","journal-title":"J Mol Graph"},{"key":"3162_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.fitote.2018.08.009","volume":"130","author":"J Zhang","year":"2018","unstructured":"Zhang J, et al. Eight new triterpenoids with inhibitory activity against HMG-CoA reductase from the medical mushroom Ganoderma leucocontextum collected in Tibetan plateau. Fitoterapia. 2018;130:79\u201388. https:\/\/doi.org\/10.1016\/j.fitote.2018.08.009.","journal-title":"Fitoterapia"},{"issue":"10","key":"3162_CR42","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1021\/jp075502e","volume":"112","author":"VB da Silva","year":"2008","unstructured":"da Silva VB, Taft CA, Silva CHTP. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA Reductase inhibitors for the treatment of hypercholesterolemia \u2020. J Phys Chem A. 2008;112(10):2007\u201311. https:\/\/doi.org\/10.1021\/jp075502e.","journal-title":"J Phys Chem A"},{"issue":"3","key":"3162_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","volume":"267","author":"G Jones","year":"1997","unstructured":"Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267(3):727\u201348. https:\/\/doi.org\/10.1006\/jmbi.1996.0897.","journal-title":"J Mol Biol"},{"issue":"11","key":"3162_CR44","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1110\/ps.036335.108","volume":"17","author":"VZ Spassov","year":"2008","unstructured":"Spassov VZ, Yan L. A fast and accurate computational approach to protein ionization. Protein Sci. 2008;17(11):1955\u201370. https:\/\/doi.org\/10.1110\/ps.036335.108.","journal-title":"Protein Sci"},{"issue":"2","key":"3162_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12551-016-0247-1","volume":"9","author":"NS Pagadala","year":"2017","unstructured":"Pagadala NS, Syed K, Tuszynski J. Software for molecular docking: a review. Biophys Rev. 2017;9(2):91\u2013102. https:\/\/doi.org\/10.1007\/s12551-016-0247-1.","journal-title":"Biophys Rev"},{"issue":"6","key":"3162_CR46","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/jcc.20634","volume":"28","author":"R Huey","year":"2007","unstructured":"Huey R, Morris GM, Olson AJ, Goodsell DS. A semiempirical free energy force field with charge-based desolvation. J Comput Chem. 2007;28(6):1145\u201352. https:\/\/doi.org\/10.1002\/jcc.20634.","journal-title":"J Comput Chem"},{"issue":"4","key":"3162_CR47","doi-asserted-by":"publisher","first-page":"303","DOI":"10.4155\/fmc-2018-0207","volume":"11","author":"C Peng","year":"2019","unstructured":"Peng C, et al. Improving the accuracy of predicting protein\u2013ligand binding-free energy with semiempirical quantum chemistry charge. Future Med Chem. 2019;11(4):303\u201321. https:\/\/doi.org\/10.4155\/fmc-2018-0207.","journal-title":"Future Med Chem"},{"issue":"2","key":"3162_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1039\/C1MD00214G","volume":"3","author":"U Uciechowska","year":"2012","unstructured":"Uciechowska U, et al. Binding free energy calculations and biological testing of novel thiobarbiturates as inhibitors of the human NAD+ dependent histone deacetylase Sirt2. MedChemComm. 2012;3(2):167\u201373. https:\/\/doi.org\/10.1039\/C1MD00214G.","journal-title":"MedChemComm"},{"issue":"9","key":"3162_CR49","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"DEV Pires","year":"2015","unstructured":"Pires DEV, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem. 2015;58(9):4066\u201372. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00104.","journal-title":"J Med Chem"},{"key":"3162_CR50","doi-asserted-by":"publisher","unstructured":"Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 46(W1):W257\u201363, 02 2018. https:\/\/doi.org\/10.1093\/nar\/gky318.","DOI":"10.1093\/nar\/gky318"},{"key":"3162_CR51","doi-asserted-by":"publisher","unstructured":"Machhar J, Mittal A, Agrawal S, Pethe AM, Kharkar PS. Computational prediction of toxicity of small organic molecules: state-of-the-art. Phys Sci Rev. 2019;4(10). https:\/\/doi.org\/10.1515\/psr-2019-0009.","DOI":"10.1515\/psr-2019-0009"},{"issue":"7","key":"3162_CR52","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/cmdc.201900034","volume":"14","author":"G Luna","year":"2019","unstructured":"Luna G, Dolzhenko AV, Mancera RL. Inhibitors of xanthine oxidase: scaffold diversity and structure-based drug design. ChemMedChem. 2019;14(7):714\u201343. https:\/\/doi.org\/10.1002\/cmdc.201900034.","journal-title":"ChemMedChem"},{"issue":"3","key":"3162_CR53","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1021\/bi401465u","volume":"53","author":"H Cao","year":"2014","unstructured":"Cao H, Hall J, Hille R. Substrate orientation and specificity in xanthine oxidase: crystal structures of the enzyme in complex with Indole-3-acetaldehyde and guanine. Biochemistry. 2014;53(3):533\u201341. https:\/\/doi.org\/10.1021\/bi401465u.","journal-title":"Biochemistry"},{"issue":"1","key":"3162_CR54","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1747-0285.2012.01339.x","volume":"80","author":"S Sakkiah","year":"2012","unstructured":"Sakkiah S, Thangapandian S, Lee KW. Ligand-based virtual screening and molecular docking studies to identify the critical chemical features of potent Cathepsin D inhibitors: Pharmacophore-based identification of potent inhibitor of Cathepsin D. Chem Biol Drug Des. 2012;80(1):64\u201379. https:\/\/doi.org\/10.1111\/j.1747-0285.2012.01339.x.","journal-title":"Chem Biol Drug Des"},{"issue":"5","key":"3162_CR55","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1021\/jm00125a025","volume":"32","author":"DN Boobbyer","year":"1989","unstructured":"Boobbyer DN, Goodford PJ, McWhinnie PM, Wade RC. New hydrogen-bond potentials for use in determining energetically favorable binding sites on molecules of known structure. J Med Chem. 1989;32(5):1083\u201394. https:\/\/doi.org\/10.1021\/jm00125a025.","journal-title":"J Med Chem"},{"issue":"3","key":"3162_CR56","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1134\/S0036023617030068","volume":"62","author":"AM Dolgonosov","year":"2017","unstructured":"Dolgonosov AM. The universal relationship between the energy and length of a covalent bond derived from the theory of generalized charges. Russ J Inorg Chem. 2017;62(3):344\u201350. https:\/\/doi.org\/10.1134\/S0036023617030068.","journal-title":"Russ J Inorg Chem"},{"key":"3162_CR57","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jphotobiol.2015.10.022","volume":"153","author":"S Lin","year":"2015","unstructured":"Lin S, Zhang G, Pan J, Gong D. Deciphering the inhibitory mechanism of genistein on xanthine oxidase in vitro. J Photochem Photobiol B. 2015;153:463\u201372. https:\/\/doi.org\/10.1016\/j.jphotobiol.2015.10.022.","journal-title":"J Photochem Photobiol B"},{"key":"3162_CR58","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ejmech.2017.04.031","volume":"135","author":"A \u0160melcerovi\u0107","year":"2017","unstructured":"\u0160melcerovi\u0107 A, et al. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity. Eur J Med Chem. 2017;135:491\u2013516. https:\/\/doi.org\/10.1016\/j.ejmech.2017.04.031.","journal-title":"Eur J Med Chem"},{"key":"3162_CR59","doi-asserted-by":"publisher","unstructured":"J. Nomura et al., \u201cXanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice,\u201d Sci. Rep., vol. 4, no. 1, p. 4554, May 2015, doi: https:\/\/doi.org\/10.1038\/srep04554.","DOI":"10.1038\/srep04554"},{"issue":"25","key":"3162_CR60","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1409065.","journal-title":"N Engl J Med"},{"issue":"7","key":"3162_CR61","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1517\/13543776.2011.577417","volume":"21","author":"R Kumar","year":"2011","unstructured":"Kumar R, Darpan SS, Singh R. Xanthine oxidase inhibitors: a patent survey. Expert Opin Ther Pat. 2011;21(7):1071\u2013108. https:\/\/doi.org\/10.1517\/13543776.2011.577417.","journal-title":"Expert Opin Ther Pat"},{"issue":"1\u20132","key":"3162_CR62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1383-5718(01)00221-2","volume":"496","author":"W-Y Chung","year":"2001","unstructured":"Chung W-Y, Jung Y-J, Surh Y-J, Lee S-S, Park K-K. Antioxidative and antitumor promoting effects of [6]-paradol and its homologs. Mutat Res Toxicol Environ Mutagen. 2001;496(1\u20132):199\u2013206. https:\/\/doi.org\/10.1016\/S1383-5718(01)00221-2.","journal-title":"Mutat Res Toxicol Environ Mutagen"},{"key":"3162_CR63","doi-asserted-by":"publisher","unstructured":"S. Bais and N. Abrol, \u201cReview on Chemistry and Pharmacological Potential of Amentoflavone,\u201d vol. 6, no. 1, pp. 16\u201322, 2016, doi: https:\/\/doi.org\/10.3923\/crn.2016.16.22.","DOI":"10.3923\/crn.2016.16.22"},{"issue":"2","key":"3162_CR64","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jep.2009.10.004","volume":"127","author":"S Dugasani","year":"2010","unstructured":"Dugasani S, Pichika MR, Nadarajah VD, Balijepalli MK, Tandra S, Korlakunta JN. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. J Ethnopharmacol. 2010;127(2):515\u201320. https:\/\/doi.org\/10.1016\/j.jep.2009.10.004.","journal-title":"J Ethnopharmacol"},{"key":"3162_CR65","doi-asserted-by":"crossref","unstructured":"Prasad S, Tyagi AK. Ginger and Its Constituents: Role in Prevention and Treatment of Gastrointestinal Cancer. Gastroenterology Research and Practice. 2015;08 https:\/\/www.hindawi.com\/journals\/grp\/2015\/142979\/ (.","DOI":"10.1155\/2015\/142979"},{"issue":"1","key":"3162_CR66","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","volume":"161","author":"JL Goldstein","year":"2015","unstructured":"Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161\u201372. https:\/\/doi.org\/10.1016\/j.cell.2015.01.036.","journal-title":"Cell"},{"key":"3162_CR67","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ejmech.2016.11.015","volume":"127","author":"K Wang","year":"2017","unstructured":"Wang K, et al. A novel class of \u03b1-glucosidase and HMG-CoA reductase inhibitors from Ganoderma leucocontextum and the anti-diabetic properties of ganomycin I in KK-A y mice. Eur J Med Chem. 2017;127:1035\u201346. https:\/\/doi.org\/10.1016\/j.ejmech.2016.11.015.","journal-title":"Eur J Med Chem"},{"issue":"20","key":"3162_CR68","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1359-6446(03)02827-7","volume":"8","author":"DE Clark","year":"2003","unstructured":"Clark DE. In silico prediction of blood\u2013brain barrier permeation. Drug Discov Today. 2003;8(20):927\u201333. https:\/\/doi.org\/10.1016\/S1359-6446(03)02827-7.","journal-title":"Drug Discov Today"},{"issue":"12","key":"3162_CR69","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s10822-011-9478-1","volume":"25","author":"M Muehlbacher","year":"2011","unstructured":"Muehlbacher M, Spitzer GM, Liedl KR, Kornhuber J. Qualitative prediction of blood\u2013brain barrier permeability on a large and refined dataset. J Comput Aided Mol Des. 2011;25(12):1095\u2013106. https:\/\/doi.org\/10.1007\/s10822-011-9478-1.","journal-title":"J Comput Aided Mol Des"},{"key":"3162_CR70","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jinorgbio.2018.03.002","volume":"183","author":"M \u0160rejber","year":"2018","unstructured":"\u0160rejber M, et al. Membrane-attached mammalian cytochromes P450: an overview of the membrane\u2019s effects on structure, drug binding, and interactions with redox partners. J Inorg Biochem. 2018;183:117\u201336. https:\/\/doi.org\/10.1016\/j.jinorgbio.2018.03.002.","journal-title":"J Inorg Biochem"},{"issue":"4","key":"3162_CR71","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/08998280.2000.11927719","volume":"13","author":"CC Ogu","year":"2000","unstructured":"Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc Bayl Univ Med Cent. 2000;13(4):421\u20133.","journal-title":"Proc Bayl Univ Med Cent"},{"key":"3162_CR72","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.apha.2018.04.007","volume":"83","author":"A Tornio","year":"2018","unstructured":"Tornio A, Backman JT. Cytochrome P450 in Pharmacogenetics: An Update. Advances in Pharmacology. 2018;83, Elsevier:3\u201332.","journal-title":"Advances in Pharmacology"},{"issue":"1","key":"3162_CR73","doi-asserted-by":"publisher","first-page":"18782","DOI":"10.1038\/s41598-019-55325-1","volume":"9","author":"R Watanabe","year":"2019","unstructured":"Watanabe R, et al. Development of an in silico prediction system of human renal excretion and clearance from chemical structure information incorporating fraction unbound in plasma as a descriptor. Sci. Rep. 2019;9(1):18782. https:\/\/doi.org\/10.1038\/s41598-019-55325-1.","journal-title":"Sci. Rep"},{"issue":"1","key":"3162_CR74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","volume":"18","author":"M Bredemeier","year":"2018","unstructured":"Bredemeier M, et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord. 2018;18(1):24. https:\/\/doi.org\/10.1186\/s12872-018-0757-9.","journal-title":"BMC Cardiovasc. Disord"},{"issue":"1","key":"3162_CR75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1124\/pr.58.1.6","volume":"58","author":"P Pacher","year":"2006","unstructured":"Pacher P, Nivorozhkin A, Szab\u00f3 C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. Mar. 2006;58(1):87\u2013114. https:\/\/doi.org\/10.1124\/pr.58.1.6.","journal-title":"Pharmacol Rev"},{"issue":"8","key":"3162_CR76","doi-asserted-by":"publisher","first-page":"543","DOI":"10.7326\/M18-0808","volume":"169","author":"Y He","year":"2018","unstructured":"He Y, et al. Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials. Ann Intern Med. 2018;169(8):543. https:\/\/doi.org\/10.7326\/M18-0808.","journal-title":"Ann Intern Med"},{"issue":"2","key":"3162_CR77","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ijpharm.2011.01.056","volume":"416","author":"M Coimbra","year":"2011","unstructured":"Coimbra M, et al. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. Int J Pharm. 2011;416(2):433\u201342. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.01.056.","journal-title":"Int J Pharm"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-020-03162-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12906-020-03162-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-020-03162-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T12:02:48Z","timestamp":1609502568000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-020-03162-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3162"],"URL":"https:\/\/doi.org\/10.1186\/s12906-020-03162-5","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"27 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}